Myriad Genetics upgraded to Neutral from Underperform at Credit Suisse Credit Suisse upgraded Myriad Genetics to Neutral based on strong quarterly results and the Crescendo acquisition that adds diversification and accretion. Price target raised to $29 from $18.
Myriad RBM joins Institut Pasteur in TB collaboration Myriad RBM, a wholly owned subsidiary of Myriad Genetics, announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis, or TB, epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis.